Dear Mr Stevens,

We’re writing as a coalition of 20 charities, health professionals and professional groups - led by Prostate Cancer UK - that work with people with a range of conditions for which erectile dysfunction treatments (ED) are funded on the NHS. We’re concerned that the men we work with do not receive the support they need to cope with and recover from ED, and that much of this is due to prescribing guidance which is out of date and not fit for purpose.

As you’ll know, ED treatments aren’t normally funded on the NHS, but men with prostate cancer, diabetes, MS, Parkinson’s disease, kidney disorders and other conditions are able to receive these treatments on the NHS. Access to them is regulated by the Department of Health’s health services circular on impotence. While we understand from Prostate Cancer UK’s previous correspondence that NHS England are not able to update this DH circular, we understand that any new guidance would need to come from NHS England and are therefore writing to ask that you work with us to develop new guidance to make sure men are able to access the ED treatments they need.

Prostate Cancer UK’s research with men, health professionals and commissioners has found that although 76% of men who are treated for prostate cancer experience erectile dysfunction, only 30% say their ED treatment met their needs and that the current prescribing guidance is a main barrier that prevents men accessing proper treatment.

The guidance was originally produced by the DH in 1999 and since then has only received piecemeal updates such as one last year which removed generic Viagra from the guidance and opened it up for wider NHS prescribing. This was a welcome change, but it didn’t go far enough. Although the guidance is meant to regulate the availability of all ED treatments, it doesn’t name new treatments such as alprostadil, or non-drug treatments such as vacuum erection devices and we know from research with health professionals that commissioners have used this to justify decisions not to fund these important treatments. The guidance also places limits on the number of tablets men can access per month. For men with prostate cancer treatment-induced ED, this has a huge impact on their ability to recover due to the fact that a proper penile rehabilitation strategy relies on a man having sufficiently frequent erections (either drug or device assisted) in order to give him the best chance of returning to his pre-treatment baseline erectile function and reduce his reliance on drugs and other treatments in the longer term.
Our clinical advisors also tell us that because the eligibility for ED treatments is restricted by disease and treatment groups, men who also have a treatment-induced physical cause for their ED resulting from a condition that is not specifically named are often denied treatment. This includes men who receive pelvic radiotherapy for a primary malignancy that is not named, men treated by radical radiotherapy or chemoradiotherapy for rectal or anal cancer or pelvic sarcomas and those having total body irradiation or systemic treatment for leukaemia or lymphoma, and men who are treated by androgen deprivation therapy for male breast cancer.

As I’m sure you can imagine erectile dysfunction has a huge impact on men and their relationships. Seventy eight per cent of men with treatment-induced erectile dysfunction, told Prostate Cancer UK that they found, or continue to find, it ‘difficult’ or ‘very difficult’ to deal with. More than half of these men said their erectile dysfunction had a negative impact on how they felt about themselves, citing depression, sadness, inadequacy, low self esteem and loss of masculinity. Forty seven per cent said that erectile dysfunction had negatively affected their relationship. And, polling by Relate found that, unfortunately, 91% of people with a long term health condition or disability were unaware that relationship support was available to them1.

We’d very much like to work with you to produce new prescribing guidance for these treatments that provides commissioners with up to date and clinically effective information on the types of ED treatments they should be providing for men with relevant conditions. Prostate Cancer UK’s research with commissioners has shown that 95% of Clinical Commissioning Groups still use the DH guidance. So, although it is out of date, we know that it informs commissioning decisions so developing new guidance that is up to date and fit for purpose is an important first step in ensuring men have access to the treatments they need, regardless of where they live. New guidance will be of real benefit to over two million men across the country.

We would be very grateful for your thoughts on this issue and how we can work together to address this situation. We’d be very happy to meet to discuss this further if that would be helpful. If you’d like to arrange a time to meet myself and other members of this coalition, I’d be grateful if you could contact Meaghan Kerr on 0203 310 7012 or by email to meaghan.kerr@prostatecanceruk.org.

Yours sincerely

Owen Sharp
Chief Executive
Prostate Cancer UK

Please see overleaf for supporting organisations and health professionals

cc Bruce Warner, Deputy Chief Pharmaceutical Officer, NHS England
    Stuart Merritt, Medicines, Pharmacy & Industry, Department of Health

1 Relate (2015) Link Between Relationships and Health Ignored in the NHS (http://is.gd/sBFZ9N)
Supporting organisations and health professionals

Fiona Sexton  
President  
British Association of Urological Nurses (BAUN)

Dr Frank Chinegwundoh  
Chairman  
Cancer Black Care

Chris Booth FRCS  
Clinical Director  
CHAPS - The Men’s Health Charity

Bridget Turner  
Director of Policy and Care Improvement  
Diabetes UK

Nick Turkentine  
Chief Operating Officer  
James Whale Fund for Kidney Cancer

Tony Gavin  
Director of Campaigning and Advocacy  
Leukaemia CARE

Juliet Bouverie  
Director of Services and Influencing  
Macmillan Cancer Support

Martin Tod  
Chief Executive  
Men’s Health Forum
Rebecca Porta  
Chief Executive  
Orchid Cancer Appeal

Steve Ford  
Chief Executive Officer  
Parkinson’s UK

Keith Cass  
Founder  
The Red Sock Campaign

Ruth Sutherland  
Chief Executive Officer  
Relate

Amanda Baxter  
Uro-oncology Clinical Nurse Specialist

Dr Isabel White  
Clinical Research Fellow in Psychosexual Practice  
The Royal Marsden NHS Foundation Trust

Loraine Grover  
Trustee  
The Sexual Advice Association

Rowena Bartlett  
Chief Executive

Roger Wotton  
Chairman  
Tackle Prostate Cancer

Professor M G Kirby  
Visiting Professor, Faculty of Health and Human Sciences, Centre for Research in Primary and Community Care, University of Hertfordshire